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Abstract
Background: A synergistic cytotoxic effect has been hypothesized for taxanes and capecitabine,
a prodrug of 5-fluorouracil. Based on preclinical studies, this synergism has been attributed to an
up-regulation of the enzyme thymidine phosphorylase (TP). Beside tumour tissue, TP is highly
expressed in white blood cells, possibly causing increased hematotoxicity, when taxanes are
combined with capecitabine. So far, this hypothesis has not been investigated in humans.
Methods: A total of 128 consecutive blood samples were collected from eight patients with
advanced breast cancer receiving paclitaxel weekly at a dose of 80 mg/m2. To assess the expression
of TP in blood cells, samples were collected prior to first therapy, at the end of infusion, and up to
15 days thereafter. This procedure was repeated during the sixth application of paclitaxel. After
isolation of the peripheral mononuclear blood cells, the expression of TP was assessed by ELISA.
In parallel, paclitaxel level in plasma was evaluated at three selected time points as pharmacokinetic
control parameter.
Results: Paclitaxel concentrations at the end of infusion did not change significantly from week 1
to week 6. The expression of TP in peripheral mononuclear blood cells decreased significantly after
infusion below pretherapeutic values (p = 0.023; n = 8). After the nadir on day 3, the expression of
TP increased moderately returning to baseline levels within one week. The overall picture in week
6 was similar to week 1. Using a trend analysis, neither a short-term nor a long-term induction of
TP was observed.
Conclusion: TP in peripheral mononuclear blood cells was hardly regulated under therapy with
paclitaxel. Therefore, no increased haematotoxicity due to TP upregulation is expected from the
combination of taxanes and capecitabine.
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Background
In advanced breast cancer, combinations of cytotoxic
agents with synergistic antitumour effect deserve particu-
lar attention. Different groups reported increased
response rates and prolonged time to disease progression
in combination therapy as compared to single-agent treat-
ment. Yet, combining cytotoxic drugs is usually associated
with increased toxicity. A synergistic effect has been
hypothesized for paclitaxel and capecitabine, a prodrug of
5-fluorouracil. Taxanes are a group of compounds that
interact with the β subunit of tubulin and induce tubulin
polymerization thus interfering with the normal balance
between polymerization and its contrary, depolymerisa-
tion. This mechanism eventually leads to the arrest in the
G2/M phase of the cell cycle with subsequent cell death
[1].
The parent drug capecitabine, on the other hand, has no
intrinsic cytotoxic effect, but is activated via a cascade of
three enzymes to yield the well-known anticancer agent 5-
fluorouracil. The activation is completed by the enzyme
thymidine phosphorylase (TP) converting 5'-deoxy-5-
fluorouridine to 5-fluorouracil, preferentially within the
tumour cell [2]. Beside a known elevated expression of
thymidine phosphorylase within tumour cells and white
blood cells [3], paclitaxel and other agents have the ability
to induce this enzyme in the mouse model [4]. The very
pronounced up-regulation in tumours due to paclitaxel
should eventually lead to the synergistic effect of the com-
bination paclitaxel and capecitabine [5,6]. If the same
upregulation however holds true also for TP in white
blood cells, the assumed synergistic activity would
increase haematologic side effects of taxanes. Therefore
several questions remain, which need to be answered in
order to fully exploit the potential benefits of combining
paclitaxel and capecitabine in therapeutic protocols. In
particular, the scheduling of those substances appears
important for a synergistic effect [7]. Clinical studies rely-
ing on the up-regulation of thymidine phosphorylase
have already been published [6,8-10]. Yet, in contrast to
data from tumour xenograft models, corresponding data
from human tumour tissue is lacking. Furthermore, it
must be asked whether a regulation of TP in white blood
cells occurs. We have no knowledge concerning kinetics of
a possible TP induction in human white blood cells (e.g.
start of thymidine phosphorylase up-regulation, maxi-
mum expression level after single dose, decline of thymi-
dine phosphorylase expression after a single dose of the
modulating drug, maximum expression level reached
under repeated administration).
There is a vast clinical experience with paclitaxel adminis-
tered as a single agent in patients suffering from advanced
breast cancer. Initially administered every three weeks at a
dose of 175 mg/m2, dose density concepts have helped to
establish a weekly schedule with relatively mild toxicities
at 80 – 100 mg paclitaxel/m2 [11,12] and in the elderly
[13]. This concept has also been extended to combination
trials of capecitabine with a variety of anticancer agents
such as docetaxel, platinum drugs, anthracyclines, 5-fluor-
ouracil, and others [14].
From previous studies, it is known that capecitabine dis-
tributes rapidly into malignant lesions with a mean delay
of 45 minutes when compared with plasma kinetics [15].
As consequence, the putative up-regulation of thymidine
phosphorylase expression by paclitaxel would translate
into modulatory benefit with negligible time delay in
humans. It is therefore reasonable to assume that once the
induction of TP is established in humans, a more rational
approach might further exploit the synergism of paclitaxel
with capecitabine. On the other hand, optimal scheduling
to reduce haematotoxicity caused by a hypothetical TP
induction in white blood cells might also be possible.
Given the above described facts, we initiated this trial to
answer questions concerning the kinetics of TP induction
in human peripheral mononuclear cells by paclitaxel. In
parallel to serial assessment of thymidine phosphorylase
expression, three characteristic data points of paclitaxel
pharmacokinetics were used as a pharmacokinetic quality
control parameter.
Methods
All specimen and data were collected at the First Depart-
ment of Medicine and Cancer Centre, Clinical Division of
Oncology, at the Medical University of Vienna, Vienna,
Austria. The trial was performed in accordance with the
ethical regulations of the Medical University of Vienna
and has been approved by the appropriate ethics commit-
tee prior to its initiation.
Patients
A total of eight patients with histological confirmed
advanced or metastatic breast cancer were included from
February 2005 until September 2005; all eight are evalua-
ble for toxicity and response. Criteria for inclusion were as
follows: histological confirmed metastatic or locally
advanced inoperable breast cancer without prior taxane
(paclitaxel, docetaxel) treatment (adjuvant or palliative),
Karnofsky Performance Index > 80, adequate bone mar-
row function (WBC > 3.5 G/I, PLT > 100 G/l), adequate
liver- and kidney function parameters (creatinine < 1.5
mg%, bilirubin < 2.0 mg%, ASAT < 2.5 × normal, PTT >
60%), serum calcium within normal ranges, and written
informed consent. Patients under the age of 18 years, with
prior chemotherapy (adjuvant or palliative) with taxanes,
second neoplasias except cured basalioma of the skin or
cervical cancer, treatment with any investigational drug
during the last four weeks prior to recruitment to thisBMC Clinical Pharmacology 2007, 7:7 http://www.biomedcentral.com/1472-6904/7/7
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study, serious illnesses (e.g. cardiac illness, inflammatory
bowel disease, diabetes without sufficient treatment, sei-
zures,...), pregnancy, inadequate contraception, and Iacta-
tion were excluded from the study.
Treatment plan and patients evaluation
80 mg Paclitaxel/m2 (Taxol®; Bristol-Myers Squibb, Princ-
eton, NJ, USA) were administered intravenously by a 1-
hour infusion. Premedication consisted of 8 mg dexame-
thasone i.v., 50 mg diphenhydramine i.v., and 50 mg ran-
itidine i.v. 30 minutes prior to paclitaxel administration.
Serotonin receptor antagonists were administered accord-
ing to clinical routine protocols. Paclitaxel was adminis-
tered weekly for six weeks every eight weeks for a
minimum of two cycles before restaging. Tumour
response was assessed every 2 cycles using UICC criteria.
Experimental design
To assess the expression of thymidine phosphorylase in
blood cells, 8 ml blood were collected prior to therapy
(day 1), at the end of the i.v. infusion, 24 h, 48 h, and 72
h later, as well as at days 8, 11, and 15. This procedure was
repeated during the sixth application of paclitaxel (week
6).
To evaluate paclitaxel concentrations, samples of 3 ml
blood were drawn prior to therapy, at the end of the i.v.
infusion, 20 h, and 44 h after drug administration into
EDTA containing vials. After collection, blood was centri-
fuged immediately for 5 min at 3000 RPM. The plasma
was separated from blood cells and stored at -20°C until
analysis.
Peripheral mononuclear blood cells were isolated by ficoll
gradient centrifugation (Cell Preparation Tube System;
Becton-Dickinson, Franklin Lakes, NJ, USA). Sodium cit-
rate vials were used as blood containers. Recovered cells
were washed twice in phosphate buffered saline, and
lysed by sonification. As a reference, the content of total
protein is determined using a colorimetric assay (BCA
Protein Assay Kit; Pierce, Rockford, IL, USA). The expres-
sion of thymidine phosphorylase was assessed in dupli-
cates using an ELISA according to the manufacturer's
instructions (Thymidine Phosphorylase ELISA; Roche,
Mannheim, Germany).
Paclitaxel was evaluated using an HPLC method devel-
oped in our laboratory [16]. Briefly, frozen samples were
thawed under light protection, vortex-mixed, and centri-
fuged at 20,000 × g. 100 μl from the clear supernatant
were directly injected onto the HPLC system and loaded
onto a C4-ADS clean-up column with a constant flow of
methanol – water. After column-switching 10 min later,
paclitaxel was transferred in backflush mode onto the
analytical column delivering ammonium acetate buffer –
acetonitrile as a solvent. The analyte was evaluated by
monitoring the UV-absorbance at a wavelength of 229
nm.
Statistical analysis
The expression of thymidine phosphorylase was calcu-
lated as ng thymidine phosphorylase/mg protein of the
cell lysate. Results are provided as mean +/- standard devi-
ation, with outliers indicated. The kinetics of thymidine
phosphorylase expression were monitored in paclitaxel
naive patients and compared with the observed concen-
trations after six administrations of paclitaxel (paired Wil-
coxon test). Paclitaxel concentrations monitored at the
end of the infusion, one and two days later were com-
pared with previously evaluated pharmacokinetic data to
exclude outlying patients. In order to statistically describe
significant courses in thymidine phosphorylase expres-
sion vs. time, a trend analysis was performed to test for
slope deviations significantly different from zero. Statis-
tics were calculated using GraphPad PRISM version 4.00
software (GraphPad Software, San Diego, CA, USA).
Results
Patient characteristics
Eight paclitaxel naive patients with a median age of 65.5
years (range: 53 – 73 years) suffering from advanced
breast cancer were included in this evaluation. Weekly
paclitaxel was used as first line therapy in 4 patients
(50%), second line in 2 patients (25%), and beyond sec-
ond line in 2 patients (25%). Table 1 lists the characteris-
tics of the eight patients included.
Paclitaxel
The concentrations of paclitaxel at the end of the i.v. infu-
sion did not change significantly from week 1 to week 6
indicating stable pharmacokinetics in the study popula-
tion (cmax: 3480 ± 1020 nmol/L vs. 3040 ± 1510 nmol/L).
A similar observation was made when analyzing samples
24 h (plasma concentration: 33.1 ± 12.0 nmol/L vs. 28.9
± 23.4 nmol/L) and 48 h later (plasma concentration: 8.6
± 7.6 nmol/L vs. 10.9 ± 7.0 nmol/L).
Thymidine phosphorylase
In eight paclitaxel naive patients, the expression of thymi-
dine phosphorylase in peripheral mononuclear blood
cells temporarily decreased under infusion with paclitaxel
equilibrating within 24 h to enzyme levels observed prior
to therapy (Figure 1). In the next 48 hours, these levels
decreased to thymidine phosphorylase levels significantly
below pretherapeutic values resulting in a TP nadir on day
3 (p = 0.023). Only then, the expression of thymidine
phosphorylase increased moderately reaching levels simi-
lar to the baseline levels observed in paclitaxel naive
patients. The overall picture in week 6 was very similar to
that observed in week 1 with a nadir of thymidine phos-BMC Clinical Pharmacology 2007, 7:7 http://www.biomedcentral.com/1472-6904/7/7
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phorylase expression on day 3 after drug administration
(Figure 2). Considering the flat concentration-time curve
in patients, the calculation of the parameters time to max-
imum expression (tmax) and maximum concentration in
blood cells (cmax at tmax) could not be performed. Simi-
larly, the slope of the trend analysis (observation period:
15 days) was not significantly different from zero indicat-
ing a stable enzyme expression in blood cells. The maxi-
mum expression level (steady-state) of thymidine
phosphorylase in human peripheral blood cells after
repeated administration of 80 mg paclitaxel/m2 i.v. in
week 6, i.e. after six doses of paclitaxel, was very similar to
that observed in paclitaxel naive patients, but also to that
after repeated administration of paclitaxel. This congru-
ence is indicative for a stable phenotype of TP expression
in peripheral mononuclear blood cells, which is subject to
Table 1: Patient characteristics
Characteristics Patients
Entered 8
Karnofsky performance score 90–100%
Age (years)






Not available 1 (12.5%)
Ductal/Lobular 7/0





Not available 1 (12.5%)
Estrogens receptor/progesteron receptor positive 7/6
Her2 Status positive/negative (IHC/FISH*) 0/8
Adjuvant chemotherapy 3 (37.5%)
Adjuvant endocrine therapy 3 (37.5%)
Palliative endocrine therapy 4 (50%)
Prior anthracycline exposure 5 (62.5%)
Prior capecitabine exposure 2 (25%)
Time to recurrence
Median (range) 87 months (13 – 148 m)
Treatment line
First line 4 (50%)
Second line 2 (25%)
>/= Third line 2 (25%)
Metastatic sites
Median (range) 2 (range 1 – 4)











More than one metastatic site 7 (87.5%)
* IHC: immunohistochemistry, Herceptest® (Dako A/S, Glostrup, Denmark); FISH: dual colour fluorescent in situ hybridization (PathVision® HER2 
DNA probe kit, Vysis, Downers Grove, IL, USA)BMC Clinical Pharmacology 2007, 7:7 http://www.biomedcentral.com/1472-6904/7/7
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little variation for at least eight weeks in humans. Table 2
lists the arithmetic means ± standard deviation, 95% con-
fidence intervals (CI), and outliers of every measurement.
Discussion
In this trial, neither a short- nor a long-term induction of
thymidine phosphorylase was observed in peripheral
mononuclear blood cells under weekly therapy with pacl-
itaxel. Considering the observation period of 7 weeks in
total, thymidine phosphorylase was hardly regulated in
human cells either under therapy or after termination of
paclitaxel administration.
As a consequence, the assumed synergism between
capecitabine and paclitaxel due to TP induction needs to
be discussed covering aspects of haematotoxicity as well
as therapeutic efficacy.
Capecitabine in general is regarded as cytotoxic agent with
relatively low haematologic toxicity. In a small, yet rand-
omized trial comparing capecitabine and paclitaxel in
anthracyclin-pretreated patients, grade 3/4 neutropenia
was observed in only 9% of patients on capecitabine as
compared to 53% in the paclitaxel arm [17]. A more
recent study evaluated the pharmacogenetics of capecitab-
ine in advanced breast cancer patients. In the 105 patients
included, grade 3/4 haematotoxicty was observed in 6%
only [18]. The same 6% grade 3/4 haematotoxicity rate
was reported in an observational study of capecitabine in
anthracycline- and taxane-pretreated patients [19]. Tax-
anes, on the other hand, are known to be associated with
major haematological side effects, which appear to be
most pronounced with docetaxel. A large randomized
trial comparing the two taxanes in metastatic breast cancer
(both with a three weekly regimen) reported grade 3/4
neutropenia in 93.3% percent of patients treated with
docetaxel, while only 54.5% of patients on paclitaxel
experienced grade 3/4 neutropenia (p < 0.0001). The
same holds true for the incidence of febrile neutropenia
(14.9% in the docetaxel arm versus 1.8% in the paclitaxel
arm [p < 0.001]) [20].
Based on the assumed synergistic effect of taxane plus
capecitabine combinations attributed to the induction of
TP in tumour tissue, a large randomized study comparing
docetaxel as single agent with docetaxel plus capecitabine
combination in the first line therapy of metastatic breast
cancer was initiated [21]. Combination of these cytotoxic
agents resulted in improved overall response rate and
time to disease progression. Notably, addition of capecit-
abine did not add major haemotologic toxicity when
compared to docetaxel monotherapy. A recent trial con-
ducted by Blum et al evaluated the combination of weekly
paclitaxel, which is known to yield better results as com-
pared to the three weekly schedule, with capecitabine.
Again, grade 3/4 neutropenia was experienced by 13% of
patients only [10]. It may therefore be stated that capecit-
Thymidine phophorylase kinetics in peripheral mononuclear  blood cells (n = 8); week 6 Figure 2
Thymidine phophorylase kinetics in peripheral mononuclear 
blood cells (n = 8); week 6. Arithmetic means ± standard 
error of mean (SEM).
Fig 2. Thymidine phosphorylase kinetics
in peripheral mononuclear blood cells (n=8)











































Thymidine phophorylase kinetics in peripheral mononuclear  blood cells (n = 8); week 1 Figure 1
Thymidine phophorylase kinetics in peripheral mononuclear 
blood cells (n = 8); week 1. Arithmetic means ± standard 
error of mean (SEM).
Fig 1. Thymidine phosphorylase kinetics
in peripheral mononuclear blood cells (n=8)
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abine adds little toxicity to taxane therapy considering
neutropenia. Our data may in part explain the underlying
mechanism: While potentially TP activity is increased in
tumour tissue by taxane exposure, such increase is obvi-
ously not the case in peripheral mononuclear cells. There-
fore, we assume that no synergistic haematotoxicity is to
be expected. Especially the temporary decrease of TP levels
in blood cells clearly points at a favourable time profile
for the combination of both compounds. Our results
however are limited by two factors. First, although a total
of 128 samples were collected, statistical power remains
relatively low with only eight patients included. Secondly,
the main haematological toxicity of paclitaxel is neutrope-
nia, i.e. a lack of polymorphonuclear white blood cells.
While the use of peripheral mononuclear blood cells is
convenient for study reasons, it is therefore possibly not
the ideal compartment to evaluate haematological toxic-
ity in detail.
Results of this trial must also be discussed in the light of
the assumed synergistic interaction of taxanes and capecit-
abine concerning tumour therapy. Considerable knowl-
edge about TP induction has been obtained, yet data stem
from preclinical models, even though the hypothesis
tested in those investigations has already been transferred
into clinical practice [6,8-10]. Concerning experimental
data, a closer look at some of the published studies does
not lead to unequivocal results. Sawada et al reported a
clear induction if thymidine phosphorylase in the mouse
model by paclitaxel. On the other hand, no major upreg-
ulation of TP in the cell culture was observed [4]. Impor-
tantly, in this trial an upregulation of human tumour
necrosis factor α (TNFα) in the xenograft model was seen,
which correlated strongly with increased TP levels. It is
therefore assumed that paclitaxel induces TNFα in stromal
cells of tumour tissue, which in turn holds responsible for
the increase of TP levels. This might further explain, why
no TP upregulation was observed in cell culture, and also
our trial did not show an upregulation in peripheral
mononuclear cells. Further, the kinetics of TP induction in
tumour cells remain less then clear: There is an early
observation of poor activity in mice when another taxane,
docetaxel and capecitabine are administered simultane-
ously or when the taxane is administered after 14 days of
continuous capecitabine treatment [7]. A similar observa-
tion has been reported in cell culture experiments com-
bining paclitaxel and another prodrug of 5-fluorouracil,
furtulon, in ovarian cancer in vitro, even after induction of
thymidine phosphorylase [22]. Therefore, further investi-
gation of taxane associated TP induction in human
tumours is warranted.
Conclusion
We conclude that taxane and capecitabine combinations
are a valuable treatment option in advanced breast cancer
with an acceptable toxicity profile. As shown in our trial,
no increase of haematologic toxicity by TP induction in
white blood cells needs to be expected. To our best knowl-
edge, these are the first data about longitudinal expression
of TP in humans under therapy with paclitaxel. Consider-
ing the lack of information about the modulation of TP in
tumour tissue, it is not clear whether peripheral mononu-
clear cells may serve as valid surrogate parameter for TP
levels in the malignant lesion. In addition, TP increase in
tumours may depend on functional tumour – stroma
interaction. Thus, trials evaluating this effect in humans
are urgently warranted.
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Table 2: Results
Week Measurement Results (TP ng/ml) (mean +/- SD; 95% CI; outliers)
1 1 299.24 ± 35.09; 95% CI 199.09 – 258.58; 283.42; 169.49
2 182.97 ± 56.18; 95% CI 136.00 – 229.93; 240.39; 93.80
3 246.77 ± 70.14; 95% CI 188.13 – 305.41; 350.41; 173.99
4 155.20 ± 72.11; 95% CI 94.92 – 215.49; 242.42; 49.57
5 170.66 ± 47.63; 95% CI 130.84 – 210.47; 232.71; 115.57
6 187.55 ± 67.24; 95% CI 131.33 – 243.76; 295.48; 79.59
7 200.79 ± 105.45; 95% CI 112.64 – 288.95; 369.96; 17.24
8 196.36 ± 139.83; 95% CI 79.46 – 313.27; 431.39; 4.74
6 1 233.98 ± 52.29; 95% CI 190.26 – 277.70; 297.52; 125.95
2 177.54 ± 76.06; 95% CI 113.95 – 241.13; 258.41; 50.44
3 179.14 ± 76.68; 95% CI 115.03 – 243.24; 273.87; 43.42
4 110.93 ± 66.80; 95% CI 55.08 – 166.77; 187.07; 20.76
5 183.81 ± 52.89; 95% CI 139.59 – 228.02; 228.32; 60.86
6 185.02 ± 70.87; 95% CI 125.77 – 244.27; 251.34; 43.74
7 232.50 ± 126.58; 95% CI 126.67 – 338.32; 371.45; 6.62
8 215.03 ± 90.78; 95% CI 139.13 – 290.92; 297.99; 7.56Publish with BioMed Central    and   every 
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